Syncona Ltd was founded in 2012 and operates as a healthcare investment company, taking an active role in identifying, developing and funding technologies with the potential to significantly impact the healthcare market of the future. Syncona can take the long view when necessary, able to concentrate investment into opportunities as technology is validated.

For further information please visit the company’s website at: www.synconaltd.com.


Woodford Investment Management is a fast-growing asset management company built on a founding philosophy of transparency and simplicity. Launched in May 2014, the company has more than £14 billion of assets under management and advice.

Further information can be found at: www.woodfordfunds.com.


Arix Bioscience PLC is a global healthcare and life science company. Headquartered in London and with an office in New York, Arix Bioscience sources and develops businesses addressing medical innovation at all stages of development and is supported with access to breakthrough academic science.

Further information can be found at: www.arixbioscience.com.


UCL Business PLC (UCLB) is a leading technology commercialisation company that supports research and innovations arising from UCL, one of the UK’s top research-led universities. UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. UCLB has a strong track record in commercialising medical technologies and provides technology transfer services to UCL’s associated hospitals: University College London Hospitals, Moorfields Eye Hospital, Great Ormond Street Hospital for Children and the Royal Free London Hospital. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from laboratory to market.

Further information can be found at: www.uclb.com.


Cormorant Asset Management, LLC (“Cormorant”) is a Boston based investment manager with investment focus in various stages of life-science and biotech companies, including startups, venture backed later stage rounds, crossover rounds, as well as public companies. Cormorant has a long investment horizon and utilizes a deep dive, scientific driven research approach to identify key variables in the company’s product and business model, and provides capital needed to foster company’s growth while developing products that can change people lives.

For further information, please contact Jay Scollins: Scollins@cormorant-asset.com


Nextech is a leading, global oncology investment firm that focuses on early, private-stage cancer companies. The firm is led by an entrepreneurial investment group with extensive biotech and early venture experience, working closely with a dedicated Scientific Board of oncology experts to evaluate and realize the most promising opportunities in the industry. Owing to its specialized approach and strategy, the Nextech team accesses world-class investment targets to advance validated, first-in class scientific breakthroughs for the benefit of cancer patients across the world. Previous investments include Blueprint Medicines (NASDAQ:BPMC), Kura Oncology (NASDAQ:KURA), and Neon Therapeutics.

Further information can be found at: www.nextechinvest.com